BioSpace News Archive

Virginia Bio, the statewide non-profit trade association for the life science industry, announces that John L. Newby II is named CEO, effective August 5, 2019.

OSF Ventures, the corporate investment arm of OSF HealthCare, has launched a second venture capital fund of $75 million to continue its strategy of supporting new technology, devices and services that offer improved and more cost efficient health care.

CBTS, a leading technology provider that delivers communications, cloud, infrastructure, and consulting solutions to clients across North America, is pleased to announce a partnership with OSHEAN, Inc., the Rhode Island nonprofit Research and Education Network (REN).

Concord Health Partners, a healthcare focused investment firm, led an investment in VitalTech Holdings, Inc. (“VitalTech”), an innovative remote patient monitoring and integrated digital health company.

US-UK collaboration involves multiple pilots which aim to increase access to innovative evidence-based psychological therapy treatment programs using virtual reality technology.

AvantGuard Monitoring Centers in partnership with the AG Cares Foundation is sponsoring its seventh-annual 5K benefit race.

Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical stage immunotherapy company, announced today that it will hold a conference call and webcast on Friday, August 9, 2019 at 8:00 a.m. ET to discuss the company’s second quarter 2019 financial and operational results.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the second quarter 2019, after the market close on Thursday, August 1, 2019.

Selvita, S.A., a leading clinical stage drug discovery company committed to developing innovative medicines for treatment of patients with cancer, announced the appointment of Setareh Shamsili, M.D., Ph.D., to the role of Chief Medical Officer.